Idelalisib is an Orally Active p110δ Inhibitor for Leukemia Research
PI3K signaling is active in many B-cell leukemia and lymphomas. Moreover, the cell surface receptors (class I isoforms p110α, p110β, p110δ, and p110γ) mediates the activation of the PI3K pathway.…